Morgan Stanley Maintains Equal-Weight on Celularity, Lowers Price Target to $5
Morgan Stanley analyst Jeffrey Hung maintains Celularity (NASDAQ:CELU) with a Equal-Weight and lowers the price target from $8 to $5.
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 41 companies made new 52-week lows.
Celularity Q2 EPS $0.32
Celularity (NASDAQ:CELU) reported quarterly earnings of $0.32 per share.
Recap of Wednesday’s Biotech Catalysts – End of The Day Summary
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate…
The Daily Biotech Pulse: FDA Tentatively Approves Avadel’s Narcolepsy Drug, European Approval Broadens AstraZeneca’s Enhertu in Breast Cancer, Pharma Giants’ Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours:
Akerna Shares Dip 53%, Here’s 78 Biggest Movers From Yesterday
Gainers
Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. Revelation Biosciences recently announced completion of dosing for Phase 1b CLEAR clinical study of REVTx-99b for the treatment of allergic rhinitis.
Zendesk, Quotient, + 40 Stocks Moving In Friday’s Mid-Day Session
Gainers
USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider.
U.S. Stocks Open Higher; CarMax Posts Upbeat Earnings
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 500 points on Friday.